SHANGHAI – While it works to maintain its dominant market share, the U.S.-based maker of Botox (onabotulinumtoxinA) has licensed a promising neurotoxin from a South Korean company.
SHANGHAI – A well-established French biotech company is working with one of China’s most authoritative state drug discovery organizations to develop a drug that could help the country tackle the growing incidence of breast cancer.
SHANGHAI – While it works to maintain its dominant market share, the U.S.-based maker of Botox (onabotulinumtoxinA) has licensed a promising neurotoxin from a South Korean company. Allergan Inc. surprised the market by licensing the unspecified neurotoxin from Seoul, South Korea-based Medytox Inc., which is set to receive a $65 million up-front payment, the largest in its history. The deal has been reported as the largest of its kind in the South Korean health care sector.
SHANGHAI – A well-established French biotech company is working with one of China’s most authoritative state drug discovery organizations to develop a drug that could help the country tackle the growing incidence of breast cancer.
SHANGHAI – The venture capital arm of Eli Lilly and Co. plans to invest in a small but rapidly growing biotech company with a strong pipeline to push forward the development of a third-generation whooping cough vaccine.
Following calls to improve supervision over clinical trials, China has launched a new online registration platform that should help improve transparency and the quality of the growing number of trials done in the country.
SHANGHAI – The venture capital arm of Eli Lilly and Co. plans to invest in a small but rapidly growing biotech company with a strong pipeline to push forward the development of a third-generation whooping cough vaccine.
Following calls to improve supervision over clinical trials, China has launched a new online registration platform that should help improve transparency and the quality of the growing number of trials done in the country.
SHANGHAI – Two Chinese biopharmaceutical firms have been added to an ongoing corruption probe in China that has already expanded to cover several multinationals.
